Teva Pharmaceutical Industries Ltd TEVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
Teva to Host R&D Day on Wednesday, November 11 in New York City
Teva Pharmaceuticals Shares Rise After FDA Approves Weltruza for Schizophrenia
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 1.17B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 16.07
- Price/Sales
- 2.99
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 32,842
- Website
- https://www.tevapharm.com
Competitors
Valuation
Metric | TEVA | VTRS | SDZ |
|---|---|---|---|
Price/Earnings (Normalized) | 16.07 | 15.74 | 50.11 |
Price/Book Value | 6.43 | 1.76 | 5.07 |
Price/Sales | 2.99 | 1.65 | 4.03 |
Price/Cash Flow | 16.79 | 9.06 | 41.44 |
Price/Earnings
TEVA
VTRS
SDZ
Financial Strength
Metric | TEVA | VTRS | SDZ |
|---|---|---|---|
Quick Ratio | 0.51 | 0.82 | 0.50 |
Current Ratio | 0.95 | 1.55 | 1.05 |
Interest Coverage | 1.42 | −0.11 | 4.66 |
Quick Ratio
TEVA
VTRS
SDZ
Profitability
Metric | TEVA | VTRS | SDZ |
|---|---|---|---|
Return on Assets (Normalized) | 6.94% | 8.21% | 7.69% |
Return on Equity (Normalized) | 35.60% | 20.56% | 18.79% |
Return on Invested Capital (Normalized) | 13.90% | 11.60% | 12.29% |
Return on Assets
TEVA
VTRS
SDZ
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|s%@g<Y?Q | LOCK|p$!$J | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|&?D^n>#Y | LOCK|&FXM | $50B | |||
| Haleon PLC ADR HLN | LOCK|QCH!?pk | LOCK|zx? | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|jG<GCTL | LOCK|M> | $34B | |||
| Viatris Inc VTRS | LOCK|>HhXs@n | LOCK|B% | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|@? | LOCK|&PN | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|$$pgF^W | LOCK|lr$ | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|>%rJ%J^ | LOCK|fgc | $4B | |||
| Perrigo Co PLC PRGO | LOCK|&<$Y&># | LOCK|Y< | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|K&V#!$ | LOCK|<@v! | $2B |
United States